Enhancement of radiation response with bevacizumab by Tien Hoang et al.
Hoang et al. Journal of Experimental & Clinical Cancer Research 2012, 31:37
http://www.jeccr.com/content/31/1/37RESEARCH Open AccessEnhancement of radiation response with
bevacizumab
Tien Hoang1*, Shyhmin Huang2, Eric Armstrong2, Jens C Eickhoff3 and Paul M Harari2Abstract
Background: Vascular endothelial growth factor (VEGF) plays a critical role in tumor angiogenesis. Bevacizumab is a
humanized monoclonal antibody that neutralizes VEGF. We examined the impact on radiation response by blocking
VEGF signaling with bevacizumab.
Methods: Human umbilical vein endothelial cell (HUVEC) growth inhibition and apoptosis were examined by crystal
violet assay and flow cytometry, respectively. In vitro HUVEC tube formation and in vivo Matrigel assays were performed to
assess the anti-angiogenic effect. Finally, a series of experiments of growth inhibition on head and neck (H&N) SCC1 and
lung H226 tumor xenograft models were conducted to evaluate the impact of bevacizumab on radiation response in
concurrent as well as sequential therapy.
Results: The anti-angiogenic effect of bevacizumab appeared to derive not only from inhibition of endothelial cell growth
(40%) but also by interfering with endothelial cell function including mobility, cell-to-cell interaction and the ability to
form capillaries as reflected by tube formation. In cell culture, bevacizumab induced a 2~3 fold increase in endothelial
cell apoptosis following radiation. In both SCC1 and H226 xenograft models, the concurrent administration of
bevacizumab and radiation reduced tumor blood vessel formation and inhibited tumor growth compared to either
modality alone. We observed a siginificant tumor reduction in mice receiving the combination of bevacizumab and
radiation in comparison to mice treated with bevacizumab or radiation alone. We investigated the impact of
bevacizumab and radiation treatment sequence on tumor response. In the SCC1 model, tumor response was strongest
with radiation followed by bevacizumab with less sequence impact observed in the H226 model.
Conclusions: Overall, these data demonstrate enhanced tumor response when bevacizumab is combined with radiation,
supporting the emerging clinical investigations that are combining anti-angiogenic therapies with radiation.
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Tumor angiogenesis is critical for tumors to grow and
spread. Four decades ago, Folkman proposed targeting
the tumor vasculature as a strategy to treat cancer [1].
Since then advances in biology have provided new tools
and knowledge in the area of angiogenesis. A key discovery
was the identification of vascular endothelial growth factor
(VEGF), a key angiogenic protein critical for the growth of
endothelial cells and development of tumor blood vessels
[2-4]. VEGF herein emerged as an attractive target for
anticancer therapy. It has been demonstrated in animal* Correspondence: txh@medicine.wisc.edu
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reproduction in any medium, provided the ormodels that neutralization VEGF could inhibit the growth
of primary tumor and metastases. In small 1–2 mm foci of
tumor cells, blocking the VEGF pathway inhibited the
“angiogenic switch”, i.e. preventing tumor transformation
from an avascular to vascular phase, thus maintaining a
quiescent state [5]. Bevacizumab is a humanized monoclo-
nal antibody which neutralizes the VEGF ligand. Since its
development in the late 1990s, the anti-tumor effects of
this anti-VEGF antibody have been studied in various pre-
clinical cancer models [6] as well as in clinical trials. The
combination of bevacizumab and cytotoxic chemotherapy
prolongs survival in patients with advanced colorectal,
lung or breast cancer. Bevacizumab is currently approved
for use in combination with chemotherapy in those dis-
eases, as well as monotherapy in recurrent glioblastoma.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bevacizumab with radiation to enhance the therapeutic
index. Radiation dose escalation is limited in most
anatomic sites by normal tissue toxicities. Therefore,
combining radiation with targeted agents such as
anti-angiogenic in an effort to augment radiation im-
pact and improve tumor control is desirable. It has
been shown that blocking VEGF with recombinant
human anti-VEGF antibody can enhance radiation re-
sponse in preclinical studies [7]. Augmentation of
tumor response was also observed when radiation
was combined with other anti-angiogenic or vascular
disrupting drugs [8-16].
The primary objective of this study was to investigate
the anti-angiogenic and anti-tumor activity of bevaci-
zumab in combination with radiation in human endo-
thelial cells as well as in H&N and lung tumor
models. We also explored the sequencing treatment
of bevacizumab and radiation.
Methods
Chemicals, cell lines and animals
Bevacizumab was provided by Genentech (South San
Francisco, CA). SCC1, a human head and neck squamous
carcinoma cell line was kindly provided by Dr. Tom Carey
(University of Michigan). The lung cancer cell line H226
was from the laboratory of Dr. Minna and Dr. Gazdar
(University of Texas Southwestern Medical School).
Supplement of all materials used in our experiments
can be found in our previous publication [15].
HUVEC growth inhibition assay
In this crystal violet assay, growing HUVEC seeded in
6-well plates (50,000 cells/well) were treated with bev-
acizumab in EGM-2 at various concentrations (0–
10 μM). After 3 days, cells were stained with crystal
violet. The method of this assay was described in de-
tail in previous publication [15]. The relative percent-
age of cell growth was calculated by comparison
between the bevacizumab-treated and control wells.
Flow cytometry analysis of HUVEC apoptosis
Growing HUVEC were treated with EGM-2 (control), bev-
acizumab 0.1 μM, radiation 6 Gy, or combined bevacizu-
mab and radiation. After 24 and 48 hours of incubation,
cells were harvested, prepared, and stained with propidium
iodide (PI) prior to flow cytometry analysis. The procedure
was described in detail in previous publication [15]. DNA
distributions were analyzed by Modfit for the proportion
of apoptotic cells.
In vitro angiogenesis (HUVEC tube formation) assay
In this assay, HUVEC (40,000 cells) were seeded atop of
matrigel membrane in the absence (control) or presence ofbevacizumab (0.5 μM and 5 μM). The method of this assay
was described in detail in previous publication [15]. The
plate was examined and photographed for the formation of
capillary-like endotubes under a phase-contrast microscopy
at 3 h, 6 h and 22 h.
In vivo angiogenesis (matrigel plug) assay
The method of this assay was described in detail in
previous publication [15]. In brief, 4 groups of mice
with H226-containing matrigel plugs were treated with IgG
(control), bevacizumab alone (1 mg/kg intraperitoneally),
radiation alone (2 Gy/fraction), or combination treatment
in which bevacizumab was administered immediately fol-
lowing radiation, twice a week for 2 weeks. At the end of
week 2, mice were injected with FITC-Dextran solution.
The plugs were removed and examined for the perfused
blood vessels. The intensity of fluorescence in captured
images was quantified by Adobe Photoshop software.
Growth inhibition assay in tumor xenograft models
A series of in vivo experiments in athymic mice bearing
SCC1 and H226 xenografts were conducted to examine
the anti-tumor activity of bevacizumab, radiation and
combined therapy in concurrent and sequential fashion.
Design and treatment schedule of those experiments are
described in the Results Section. Details on xenografts,
animal care, tumor measurement and radiation delivery
were described in previous publication [15].
Statistical analysis
Analysis of variance (ANOVA) was performed to compare
tumor volume in groups of mice treated with bevacizumab
and/or radiation with the control group. Treatment inter-
action and linear contrasts were used to evaluate the syn-
ergistic effect of the bevacizumab and radiation therapy
combination. Tumor volume was log-transformed to meet
the assumption of normality. Effects of bevacizumab and
radiation on tumor growth in mice bearing SCC1 and
H226 xenografts were analyzed using ANOVA and linear
mixed-effects models. An autoregressive correlation struc-
ture was assumed to account for correlations between
repeated measurements within an experimental unit.
Tukey’s HSD method was used to control the type 1 error
for the pairwise comparisons between treatment groups.
All p values were two sided and considered significant
when ≤0.05. Statistical analyses were performed with SAS
statistical software (version 8.2; SAS Institute, Cary, NC).
Results
Bevacizumab inhibits HUVEC proliferation in vitro and
tumor growth in vivo
In the crystal violet assay, bevacizumab induced a mod-
est inhibition of HUVEC growth at a concentration as






























Figure 1 Inhibitory effect of bevacizumab on proliferation of
HUVEC.
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0.001 μM - 10 μM with approximately 30-40% HUVEC
growth inhibition. No clear dose response effect was
observed suggesting saturation of VEGF blockade in the
higher dose range.
In the first animal experiment designed to test the
anti-tumor activity of bevacizumab in our xenograft
models, mice with SCC1 and H226 xenografts (n = 3 per
treatment group for each cell line) were treated with
IgG (control) or 3 dose levels of bevacizumab (1, 5
and 25 mg/kg i.p.) twice weekly for a total of 9 doses
(Figure 2A and B). Compared with controls, bevacizumab
at all 3 doses significantly inhibited tumor growth in bothFigure 2 Inhibitory effect of bevacizumab on tumor growth in SC
(n=3 tumors per treatment group for each cell line) were treated with: IgG (conSCC1 (p values of 0.04, 0.05, and 0.03, respectively) and
H226 groups (p values of 0.06, 0.04, and 0.01). There was
no significant statistical difference in anti-tumor activity
observed among the three bevacizumab groups. This re-
sult is consistent with other reports demonstrating the
maximal inhibitory activity of bevacizumab in tumor
xenograft models at approximately 1–2 mg/kg [6]. Based
on this result, a dose of 0.75-1 mg/kg of bevacizumab was
chosen for subsequent experiments to investigate the com-
bination of bevacizumab and radiation.Bevacizumab inhibits the formation of HUVEC
capillary-like network
In the tube formation assay, we observed a quick attach-
ment of HUVEC onto the matrigel in the control wells.
Indeed, cells mobilized on the gel, spread out and gener-
ated lateral processes to form intercellular connections
within 3 hours of seeding, with a network of endotubes well
established by 6 hours. This capillary-like network was well
maintained after 22 hours in the control wells (Figure 3A).
In the 0.5 μM bevacizumab wells, little inhibitory effect was
observed (Figure 3B). However, bevacizumab at 5 μM
clearly prevented the mobilization and generation of lateral
processes of HUVECs with only fragmented tubes being
seen (Figure 3C). As seen in the figures, the total numbers
of intact endotubes in the control, bevacizumab 0.5 μM and
bevacizumab 5 μM groups at 22 hours of incubation are 42,
39, and 0, respectively. This result suggests that bevacizu-
mab inhibits not only HUVEC growth but also endothelial
cell function.C1 (A) and H226 (B) xenograft models. Four groups of mice
trol), bevacizumab 1 mg/kg, 5 mg/kg and 25 mg/kg. Bev, bevacizumab.
Figure 3 Inhibitory effect of bevacizumab on HUVEC capillary-like network formation following 22 hours of treatment: (A) IgG (control),
(B) Bevacizumab 0.5 μM, and (C) Bevacizumab 5 μM.
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HUVEC
To investigate the apoptotic effect of radiation and
bevacizumab, we treated HUVEC with bevacizumab,
radiation, or both (Figure 4). Apoptosis was observed
in cells treated with radiation alone and combined radiation
and bevacizumab, but not in the control or bevacizumab
alone group. Moreover, this experiment demonstrated the
ability of bevacizumab to enhance radiation-induced
apoptosis in HUVEC, with 5.1% and 9.9% of cells treated
with combined therapy undergoing apoptosis after 24 and
48 hours respectively versus 2.1% and 3.2% in cells treated
with radiation alone.Concurrent administration of bevacizumab and radiation
inhibits in vivo tumor vascularization
To investigate the anti-angiogenic effect of bevacizumab
in combination with radiation, we performed an





















Figure 4 Effect of bevacizumab with and without radiation on HUVEC
bevacizumab (B), radiation (X), and combined bevacizumab and radiation (H226 tumor xenografts growing in matrigel plugs
(Figure 5): control IgG, bevacizumab alone (1 mg/kg
twice a week x 4 doses), radiation alone of 8 Gy
(2 Gy/fraction twice a week x 4 doses), and concurrent
bevacizumab and radiation. There was a reduction of
tumor blood vessels observed in mice treated with either
bevacizumab or radiation alone. However, the greatest re-
duction in tumor vascularization was observed in animals
receiving both bevacizumab and radiation. The mean
quantitative fluorescence of the tumor vasculature was sig-
nificantly lower in the combined treatment group (22.9) in
comparison to bevacizumab alone (34.8), radiation alone
(35.2), and control group (47). This experiment suggested
a synergistic interaction between bevacizumab and radi-
ation (p= 0.0054).Bevacizumab augments tumor response to radiation
In this experiment, four groups of mice bearing SCC1 or








apoptosis. Four groups of HUVEC were treated with: IgG (control),
B/X).
Figure 5 Activity of bevacizumab with and without radiation on blood vessel formation in tumor xenograft models. Four groups of mice with
H226 tumors in Matrigel plugs were treated with: IgG (control), bevacizumab (B), radiation (X), and combined bevacizumab and radiation (B/X).
Pictures depict the matrigel plugs with visible tumors and blood vessels (green signal of FITC-Dextran).
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(1 mg/kg twice a week), radiation alone (twice a week
with 2.5 Gy/fraction in SCC1 and 2 Gy/fraction in H226
models), or concurrent bevacizumab and radiation
(Figure 6A). The SCC1 and H226 groups were treated
for 4.5 weeks (9 treatments with a total irradiation
dose of 22.5 Gy) and 2 weeks (4 treatments with a
total dose of 8 Gy), respectively. The irradiation dose
and treatment schedule was chosen based on our previous
experience with the two cancer models. We have observed
that the H226 xenograft model is significantly more
sensitive to the anti-tumor effect from radiation than
the SCC1 model. The results demonstrated that mono-
therapy with either bevacizumab or radiation inhibited
tumor growth (Figure 6B and C). However, the strongestFigure 6 Anti-tumor activity of bevacizumab and radiation given conc
with SCC1 and H226 tumors were treated with: IgG (control), bevacizumab
Treatment schedule, and tumor growth inhibition in (B) SCC1 and (C) H226inhibitory effect was observed with the concurrent admin-
istration of bevacizumab and radiation.
Impact of treatment sequence of bevacizumab and radiation
This experiment involved 6 groups of mice bearing H226
or SCC1 tumors: (n = 16 tumors per treatment group for
each cell line) [1] Control IgG, [2] Bevacizumab
(0.75 mg/kg twice a week), [3] Radiation (twice a week
with 2.5 Gy/fraction in SCC1 and 2 Gy/fraction in H226
models), [4] Concurrent bevacizumab and radiation, [5]
Bevacizumab followed by radiation, and [6] Radiation
followed by bevacizumab (Figure 7A). The duration of
bevacizumab or radiation treatment was 2.5 weeks
(SCC1) and 1.5 weeks (H226). The total irradiation dose
was 12.5 Gy (SCC1) and 6 Gy (H226). In the sequentialurrently in SCC1 and H226 xenograft models. Four groups of mice
(B), radiation (X), and concurrent bevacizumab and radiation (B/X). (A)
models (n = 8 tumors per treatment group for each cell line).
Figure 7 Impact of treatment sequence with bevacizumab and radiation. Six groups of mice with SCC1 and H226 tumors were treated with:
IgG (control), bevacizumab (B), radiation (X), concurrent bevacizumab and radiation (B/X), bevacizumab followed by radiation (B⇒X), and radiation
followed by bevacizumab (X⇒B). (A) Treatment schedule, and tumor growth inhibition in (B) SCC1 and (C) H226 models (n = 16 tumors per
treatment group for each cell line).
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bevacizumab or radiation before switching to the other
therapy. The purpose of this experiment is to evalu-
ate the impact of treatment sequence of bevacizumab
and radiation (groups 4, 5 and 6). There was an in-
crease in tumor inhibition with combined regimens
in concurrent or sequential fashion compared to
monotherapy. Furthermore, among the three SCC1
combination therapy groups, it appeared that tumor
response was strongest with radiation followed by
bevacizumab (Figure 7B). By day 81, tumors in this
group had a mean tumor volume< 200 mm3, while
tumors in the other two combined treatment groups
regrew (> 400 mm3) after a period of response. This
impact of treatment sequence on tumor response was
not observed in the H226 experiment, with no sig-
nificant difference in anti-tumor activity seen within
the three combined treatment groups (Figure 7C).Discussion
In this current study, we confirm the ability of the
anti-VEGF monoclonal antibody bevacizumab to inhibit
endothelial cell proliferation and disrupt the formation of
capillary-like networks in culture. In the H&N and lung
cancer xenograft models, treatment with bevacizumab
inhibited tumor vascularization and inhibited volume
growth of both SCC1 and H226 tumors. However, the
growth inhibitory effect of bevacizumab is not complete,
suggesting the potential value of combining bevacizumab
with other cytotoxic modalities, such as radiation to achieve
more potent therapeutic effects.In this work, we demonstrate that radiation combined
with bevacizumab reduced the formation of tumor
vasculature and inhibited tumor growth in SCC1 and
H226 cancer xenograft models more strongly than either
modality alone (Figure 6). This is consistent with
prior work using the recombinant human monoclonal
anti-VEGF 165 antibody in mouse models bearing
other human cancers [7]. Our findings confirm that
neutralizing the VEGF ligand with bevacizumab can
augment tumor response to radiation. Works from
our laboratory and others have previously demonstrated
that radiation response is enhanced by blocking the VEGF
signaling pathway using small molecule VEGF receptor
tyrosine kinase inhibitors such as ZD6474 [11], SU6668
[12] and PTK787/ZK222584 [13], or by directly targeting
tumor blood vessels with vascular targeting agents such as
ZD6126 [14,15] and combretastatin [16].
The anti-tumor effect of this combination approach is
consistent with the two-compartment model described
by Folkman [17]. According to this model, tumors are
comprised of distinct compartments including tumor
cells and endothelial cells. By targeting the endothelial
cell compartment, bevacizumab not only inhibits the
supply of oxygen and nutrients to the tumor, but also
interrupts the “paracrine effect” by inhibiting endothelial
secretion of growth factors such as IGF1, bFGF, and
HB-EGF, which can stimulate tumor proliferation. In
parallel, by targeting the tumor compartment, radiation
kills cancer cells and thereby shuts down their produc-
tion of “pro-angiogenic” factors, thus indirectly affecting
the endothelial compartment. We have also observed
that treatment with radiation can inhibit endothelial cell
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(nonpublished data), suggesting direct inhibitory effects of
radiation on this compartment.
A current question of interest in clinical trial design
regards the optimal sequencing of radiation and anti-
angiogenic drugs to achieve maximal benefit. A valid
concern is whether targeting the tumor vasculature
will decrease tumor blood perfusion, resulting in
tumor hypoxia, and thereby diminishing the effects of
radiation. To investigate the impact of treatment se-
quencing on tumor response, we designed sequence
experiments as described in Figure 7. In the SCC-1
model, it appeared that tumor control was best
achieved with the regimen of radiation followed by
bevacizumab. This result supports the hypothesis that
hypoxia induced by bevacizumab may hinder radiation
effect. However, we found no clear difference between
sequence regimens in the H226 tumors.
Consistent with our observation in the SCC-1 tumors,
preclinical studies have shown that delivering ZD6126
prior to radiation to U87 glioblastoma xenografts resulted
in acute drop in tumor oxygen tension and attenuation of
the killing effects of radiation [18]. Further, in KHT
sarcoma models, the strongest anti-tumor activity was
achieved when ZD6126 was administered one hour
following radiation [14]. These observations suggest a
negative impact of ZD6126-induced hypoxia on radiation
effect. However, the concept of normalization of tumor
vasculature proposed by Jain et al. supports a strategy of
using anti-angiogenic drugs to improve efficacy of
radiation [19]. This theory suggests that short term
treatment of anti-angiogenic agents may “normalize” the
network of abundant but chaotic, leaky and dysfunctional
tumor vasculature, thus restore the integrity and function
of the blood vessels, leading to a decrease in interstitial
fluid pressure and the improvement in tumor oxygenation
[19]. Therefore, this process of vascular normalization
could enhance the tumor killing activity of radiation as
well as improve drug delivery into the tumor [19].
Although the induction of vascular normalization by anti-
angiogenic agents has been supported by preclinical
studies [20], it remains a challenge to capture the
transient “tumor oxygenation window” for the delivery
of radiation. We are commencing real-time imaging of
tumor hypoxia profiles in animals during treatment to
help explore optimal strategies for this combined
therapy.
In the clinic, several clinical phase I/II studies have been
conducted to investigate the safety and efficacy of radiation
and bevacizumab in cancer patients. The first report came
from a series of 6 patients with locally advanced rectal
carcinoma who were treated in a phase I trial with
induction therapy of bevacizumab (5 mg/kg x 1 dose)
followed by radiation in combination with bevacizumab and5-fluorouracil, then surgical resection [21]. This pilot study
demonstrated that a single dose of bevacizumab induction
lead to a significant decrease in interstitial fluid pressure,
tumor blood perfusion, and microvascular density on day
12 [21]. The subsequent phase II trial in the same patient
population demonstrated that bevacizumab induction ther-
apy followed by concurrent bevacizumab and chemoradia-
tion appeared safe and active with a 5-year local control
and overall survival of 100% [22]. The combination of beva-
cizumab with radiation was also investigated in early
clinical studies in other diseases including pancreatic
cancer [23] and head and neck cancer [24], in which beva-
cizumab was started either prior or concurrently with
chemoradiation.
Conclusions
In conclusion, the current study demonstrates enhanced
tumor response when bevacizumab is combined with
radiation. These data support the strategy of blocking
the VEGF signaling pathway and targeting tumor blood
vessels to improve the therapeutic index of radiation.
Important questions remain including optimization of
modality sequencing to achieve best outcome. Further
molecular and genetic knowledge regarding angiogen-
esis, interaction between radiation and tumor, blood
vessels as well as microenvironment are needed. New
imaging tools that capture real time changes in tumor
oxygenation may provide further guidance regarding
optimal sequencing of combined antiangiogenic therap-
ies and radiation. Further studies of anti-angiogenic
drugs and irradiation in non-squamous carcinoma lung
and squamous carcinoma H&N models are warranted.
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